Hsiang-Chun Chen

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia et al. · Clinical Cancer Research · 2015 · 290 citations · Full text

Medicine, Oncology, Urology +17

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti et al. · The Lancet Oncology · 2021 · 277 citations · Full text

Medicine, Oncology, Pharmacology +16

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

Johann S. de Bono, Niven Mehra, Celestia S. Higano et al. · Journal of Clinical Oncology · 2020 · 44 citations

Medicine, Oncology, Pharmacotherapy +16

TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal, Fred Saad, Arun Azad et al. · Future Oncology · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal, Arun Azad, Karim Fizazi et al. · Journal of Clinical Oncology · 2022 · 26 citations

Medicine, Oncology, Pharmacology +16